Highly Selective Inhibitors of Dipeptidyl Peptidase 9 (DPP9) Derived from the Clinically Used DPP4-Inhibitor Vildagliptin
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Siham Benramdane und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Vildagliptin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Dipeptidyl peptidase 9 (DPP9) is a proline-selective serine protease that plays a key role in NLRP1- and CARD8-mediated inflammatory cell death (pyroptosis). No selective inhibitors have hitherto been reported for the enzyme: all published molecules have grossly comparable affinities for DPP8 and 9 because of the highly similar architecture of these enzymes' active sites. Selective DPP9 inhibitors would be highly instrumental to address unanswered research questions on the enzyme's role in pyroptosis, and they could also be investigated as therapeutics for acute myeloid leukemias. Compounds presented in this manuscript (42 and 47) combine low nanomolar DPP9 affinities with unprecedented DPP9-to-DPP8 selectivity indices up to 175 and selectivity indices >1000 toward all other proline-selective proteases. To rationalize experimentally obtained data, a molecular dynamics study was performed. We also provide in vivo pharmacokinetics data for compound 42.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
- Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
- Laboratory of Microbiology, Parasitology and Hygiene, Department of Biomedical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
ORCID-Profile: Koen Augustyns, Hans De Winter, Pieter Van der Veken
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Benramdane, S., De Loose, J., Filippi, N., Espadinha, M., Beyens, O., Rymenant, Y. V., Dirkx, L., Bozdag, M., Feijens, P. B., Augustyns, K., Caljon, G., De Winter, H., De Meester, I., & Van der Veken, P. (2023). Highly Selective Inhibitors of Dipeptidyl Peptidase 9 (DPP9) Derived from the Clinically Used DPP4-Inhibitor Vildagliptin. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00609
Vancouver
Benramdane S, De Loose J, Filippi N, Espadinha M, Beyens O, Rymenant YV, et al. Highly Selective Inhibitors of Dipeptidyl Peptidase 9 (DPP9) Derived from the Clinically Used DPP4-Inhibitor Vildagliptin. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00609
BibTeX
@article{Benramdane2023,
author = {Benramdane, Siham and De Loose, Joni and Filippi, Nicolò and Espadinha, Margarida and Beyens, Olivier and Rymenant, Yentl Van and Dirkx, Laura and Bozdag, Murat and Feijens, Pim-Bart and Augustyns, Koen and Caljon, Guy and De Winter, Hans and De Meester, Ingrid and Van der Veken, Pieter},
title = {Highly Selective Inhibitors of Dipeptidyl Peptidase 9 (DPP9) Derived from the Clinically Used DPP4-Inhibitor Vildagliptin},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00609}
}
EUVIMED